Mereo BioPharma Group PLC ADR (MREO) - Net Assets
Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) has net assets worth $34.05 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($40.61 Million) and total liabilities ($6.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Mereo BioPharma Group PLC ADR's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $34.05 Million |
| % of Total Assets | 83.85% |
| Annual Growth Rate | -8.69% |
| 5-Year Change | -65.62% |
| 10-Year Change | -48.38% |
| Growth Volatility | 52.46 |
Mereo BioPharma Group PLC ADR - Net Assets Trend (2015–2025)
This chart illustrates how Mereo BioPharma Group PLC ADR's net assets have evolved over time, based on quarterly financial data. See Mereo BioPharma Group PLC ADR (MREO) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Mereo BioPharma Group PLC ADR (2015–2025)
The table below shows the annual net assets of Mereo BioPharma Group PLC ADR from 2015 to 2025. For live valuation and market cap data, see Mereo BioPharma Group PLC ADR (MREO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $40.92 Million | -32.89% |
| 2024-12-31 | $60.97 Million | +20.64% |
| 2023-12-31 | $50.54 Million | -1.68% |
| 2022-12-31 | $51.40 Million | -56.81% |
| 2021-12-31 | $119.01 Million | +681.28% |
| 2020-12-31 | $-20.47 Million | -138.39% |
| 2019-12-31 | $53.33 Million | +62.73% |
| 2018-12-31 | $32.77 Million | -47.55% |
| 2017-12-31 | $62.48 Million | -21.16% |
| 2016-12-31 | $79.26 Million | -21.94% |
| 2015-12-31 | $101.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mereo BioPharma Group PLC ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48882903900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.13 Million | 7.66% |
| Other Comprehensive Income | $-10.82 Million | -26.45% |
| Other Components | $549.62 Million | 1343.29% |
| Total Equity | $40.92 Million | 100.00% |
Mereo BioPharma Group PLC ADR Competitors by Market Cap
The table below lists competitors of Mereo BioPharma Group PLC ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Donkeyrepublic Holding AS
CO:DONKEY
|
$48.79 Million |
|
Mangalam Organics Limited
NSE:MANORG
|
$48.83 Million |
|
Heidelberger Beteiligungsholding AG
F:IPOK
|
$48.83 Million |
|
Joong Ang Enervis Co. Ltd
KQ:000440
|
$48.84 Million |
|
Thai Solar Energy Public Company Limited
BK:TSE
|
$48.79 Million |
|
Pharmx Technologies Ltd
AU:PHX
|
$48.78 Million |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
$48.77 Million |
|
Promateris SA
RO:PPL
|
$48.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mereo BioPharma Group PLC ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 60,969,000 to 40,916,000, a change of -20,053,000 (-32.9%).
- Net loss of 41,878,000 reduced equity.
- New share issuances of 39,000 increased equity.
- Other comprehensive income increased equity by 8,026,000.
- Other factors increased equity by 13,760,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-41.88 Million | -102.35% |
| Share Issuances | $39.00K | +0.1% |
| Other Comprehensive Income | $8.03 Million | +19.62% |
| Other Changes | $13.76 Million | +33.63% |
| Total Change | $- | -32.89% |
Book Value vs Market Value Analysis
This analysis compares Mereo BioPharma Group PLC ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $0.31 | x |
| 2016-12-31 | $1.77 | $0.31 | x |
| 2017-12-31 | $4.53 | $0.31 | x |
| 2018-12-31 | $2.30 | $0.31 | x |
| 2019-12-31 | $2.98 | $0.31 | x |
| 2020-12-31 | $-0.30 | $0.31 | x |
| 2021-12-31 | $1.02 | $0.31 | x |
| 2022-12-31 | $0.43 | $0.31 | x |
| 2023-12-31 | $0.38 | $0.31 | x |
| 2024-12-31 | $0.41 | $0.31 | x |
| 2025-12-31 | $0.26 | $0.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mereo BioPharma Group PLC ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -102.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8375.60%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.12x
- Recent ROE (-102.35%) is below the historical average (-53.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -12.00% | 0.00% | 0.00x | 1.06x | $-22.34 Million |
| 2016 | -35.82% | 0.00% | 0.00x | 1.09x | $-36.32 Million |
| 2017 | -62.09% | 0.00% | -0.03x | 1.54x | $-45.05 Million |
| 2018 | -97.74% | 0.00% | 0.00x | 2.05x | $-35.31 Million |
| 2019 | -83.36% | 0.00% | 0.00x | 2.15x | $-49.78 Million |
| 2020 | 0.00% | -53391.63% | 0.00x | 0.00x | $-207.78 Million |
| 2021 | 14.43% | 34.90% | 0.29x | 1.44x | $5.27 Million |
| 2022 | -81.95% | -2795.09% | 0.02x | 1.51x | $-47.26 Million |
| 2023 | -58.31% | -294.66% | 0.15x | 1.32x | $-34.52 Million |
| 2024 | -70.94% | 0.00% | 0.00x | 1.25x | $-49.35 Million |
| 2025 | -102.35% | -8375.60% | 0.01x | 1.12x | $-45.97 Million |
Industry Comparison
This section compares Mereo BioPharma Group PLC ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mereo BioPharma Group PLC ADR (MREO) | $34.05 Million | -12.00% | 0.19x | $48.79 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more